Drug therapy in Alzheimer disease: an update for the oral health care provider.
Alzheimer disease (AD) is a progressive neurologic disorder that manifests as memory loss, personality changes, global cognitive dysfunction, and functional impairment. As the United States population continues to age, the prevalence of AD will rise. Accordingly, oral health care providers will be more likely to treat patients affected by this disease; therefore, it is necessary to understand the pharmacologic agents used for the management of AD. This article provides an update of the available drug therapies for AD and discusses their implications on the oral and dental health of patients.
Turner
Lena N
LN
Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia, PA 19104, USA.
Balasubramaniam
Ramesh
R
Hersh
Elliot V
EV
Stoopler
Eric T
ET
D000544:Alzheimer Disease / Q000188:drug therapy*; D000682:Amyloid / Q000037:antagonists & inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000928:Antidepressive Agents / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects; D001569:Benzodiazepines / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000009:adverse effects; D017742:Dental Care for Chronically Ill; D004347:Drug Interactions; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D020441:Ginkgo biloba / Q000009:adverse effects; D006801:Humans; D010936:Plant Extracts / Q000009:adverse effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D014987:Xerostomia / Q000139:chemically induced
D000682:Amyloid; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D002800:Cholinesterase Inhibitors; D010936:Plant Extracts; D016194:Receptors, N-Methyl-D-Aspartate; D001569:Benzodiazepines